Gilead Sciences, Inc. (GILD)
NASDAQ • Healthcare
January 21, 2026 at 19:18 UTC
Name
CEO
Website
Industry
Year Founded
Employees
Gilead Sciences, Inc. is a biopharmaceutical company focused on antiviral and immunology therapies that are used by health systems around the world. The portfolio spans treatments for infectious diseases and serious chronic conditions, with programs that move from discovery to access through a single, repeatable pathway. Research groups work with clinical partners to translate science into medicines that can be delivered at scale, while medical affairs teams support appropriate use in real settings. Manufacturing and quality systems favor reliability over showy launches, so supply stays steady as demand shifts between regions. The company operates across the Americas, Europe, and Asia with a consistent emphasis on safety, evidence, and responsible distribution. In coverage of large-cap biotech, Gilead Sciences, Inc. stock (GILD) often marks investor interest in therapeutic franchises that combine established use with ongoing research.
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Gilead Sciences, Inc.'s Technical Indicators Summary
GILD is showing a bullish technical profile as its current price comfortably exceeds key moving averages across short, medium, and long-term horizons, indicating an established upward trend. Momentum indicators such as the MACD and Momentum (10) reinforce this positive bias, while the RSI and CCI remain neutral, suggesting room for further movement without overextension. Although the ADX points to moderate trend strength, the steady on-balance volume supports sustained buying interest. Volatility is relatively stable, with the ATR reflecting modest price fluctuation. Overall, the technical signals align to depict a constructive environment for GILD, highlighted by strong moving average support and positive momentum. The technical takeaway: GILD maintains a firm bullish stance with healthy momentum and volume backing.
| Indicator | Value |
|---|---|
RSI (14) | 54.82 |
Stochastic %K (14, 3, 3) | 73.90 |
CCI (20) | 52.74 |
WPR (14) | -4.29 |
Momentum (10) | 3.31 |
MFI | 42.92 |
MACD Level (12, 26) | 0.05 |
Bollinger Bands | $119.05 - $126.78 |
ATR (14) | $3.20 (2.56%) |
ADX (14) | 13.11 |
OBV | 218,774,800 |
Simple Moving Averages | $114.41 - $123.13(5 indicators) |
Exponential Moving Averages | $115.20 - $122.69(5 indicators) |
Get premium market insights delivered directly to your inbox.
The day started with a slight downside bias as GILD opened -0.330% lower at 123.73 versus 124.14. Early options trading in GILD is strongly risk-off, as PCR spikes to 1.71. GILD opened slightly lower amid risk-off options and mixed headlines, with no clear single driver.
Price Change
from $124.14 close
+$2.26
Trading Volume
Below avg (7.0M)
971.8K
vs S&P 500 Today
Outperforming Market
+1.40%
52-Week Position
Near highs
93.8%
Updated: January 21, 2026 at 15:34 UTC
Christmas Eve early close shapes U.S. markets
December 24, 2025